Iparomlimab/Tuvonralimab + chemo + olaparib for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a PARP inhibitor (olaparib) for people whose ovarian cancer came back at least 6 months after finishing platinum-based chemo. The goal is to see if this approach is safe and works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have recurrent ovarian cancer that is not the mucinous type.
- Your cancer came back at least 6 months after your last platinum chemotherapy, and this is your first or second recurrence.
- You cannot have surgery for your current recurrence.
- You have at least one tumor that can be measured on a scan.
- You are generally healthy enough for daily activities (ECOG score 0-1).
- You have not taken olaparib before, and if you have taken a different PARP inhibitor, it was long enough ago and your cancer stayed away for a certain time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy or with targeted therapy (Olaparib) given before surgery for advanced ovarian cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients who are not candidates for immediate surgery.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.